Drug Trial Radar · NCT03227224
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
287
Actual
Start
Aug 16, 2017
Primary completion
Jan 12, 2019
Study completion Jan 19, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.
Conditions
- Depressive Disorder, Major
Interventions
PlaceboDrug
Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
JNJ-42847922Drug
Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 6
- Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and TolerabilityTime frame: Up to Week 8
- Percentage of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Up to Week 8
- Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8Time frame: Baseline and Day 8
- Change From Baseline in Vital Signs (SBP and DBP) at Day 22Time frame: Baseline and Day 22
- Change From Baseline in Vital Signs (SBP and DBP) at Day 42Time frame: Baseline and Day 42
- Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
- Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8Time frame: Baseline and Day 8
- Change From Baseline in Vital Sign (PR) at Day 22Time frame: Baseline and Day 22
- Change From Baseline in Vital Sign (PR) at Day 42Time frame: Baseline and Day 42
- Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
- Change From Baseline in Vital Sign (Temperature) at Day 8Time frame: Baseline and Day 8
- Change From Baseline in Vital Sign (Temperature) at Day 22Time frame: Baseline and Day 22
- Change From Baseline in Vital Sign (Temperature) at Day 42Time frame: Baseline and Day 42
- Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
- Change From Baseline in Physical Examination (Waist Circumference) at Day 42Time frame: Baseline and Day 42
- Change From Baseline in Physical Examination (Body Weight) at Day 42Time frame: Baseline and Day 42
- Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42Time frame: Baseline and Day 42
- Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined LimitsTime frame: Up to Week 6
- Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 8
- Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42Time frame: Baseline and Day 42
- Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43Time frame: Day 43
- Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56Time frame: Day 49 to Day 56
Locations
101 sites in 8 countries. Site status is shown where the registry gives one.
California Pharmaceutical Research Institute, Inc.
Anaheim, California
Catalina Research Institute
Chino, California
Synergy Clinical Research Center Of Escondido
Lemon Grove, California
Asclepes Research
Panorama City, California
Sharp Mesa Vista Hospital
San Diego, California
SF-Care, Inc
San Rafael, California
Collaborative NeuroScience Network
Torrance, California
Elite Clinical Trials
Wildomar, California
Sarkis Clinical Trials
Gainesville, Florida
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida
Clinical NeuroScience Solutions Inc
Jacksonville, Florida
Innovative Clinical Research Inc
Lauderhill, Florida
Qps-Mra, Llc
Miami, Florida
Galiz Research
Miami Springs, Florida
Behavioral Clinical Research , Inc
North Miami, Florida
Clinical NeuroScience Solutions Inc
Orlando, Florida
Compass Research LLC
Orlando, Florida
Emory University
Atlanta, Georgia
Radiant Research, Inc.
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
NeuroTrials Research, Inc.
Atlanta, Georgia
Chicago Research Center
Chicago, Illinois
Great Lakes Clinical Trials
Chicago, Illinois
Joliet Center for Clinical Research
Joliet, Illinois
Clinilabs
New York, New York
Richmond Behavioral Associates
Staten Island, New York
Clinical Trials of America
Winston-Salem, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Neuro Behavioral Clinical Research
Canton, Ohio
Midwest Clinical Research Center
Dayton, Ohio
Suburban Research Associates
Media, Pennsylvania
Family Psychiatry of The Woodlands
The Woodlands, Texas
Core Clinical Research
Everett, Washington
Mental Health Center Prof. Dr. Ivan Temkov
Burgas, Bulgaria
State Psychiatric Hospital Kardzhali
Kardzhali, Bulgaria
State Psychiatric Hospital - Lovech
Lovech, Bulgaria
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, Bulgaria
MC 'Hipokrat - N', EOOD
Plovdiv, Bulgaria
Mental Health Center - Rousse
Rousse, Bulgaria
MHC - Sofia, EOOD
Sofia, Bulgaria
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.